Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Posted by GlobeNewswire on August 03, 2026

-------- Original Version -----------

Oculis announces positive FDA Pre-IND feedback supporting Privosegtor development strategy for treatment of acute multiple sclerosis relapses.

-------- English Version ------------

Oculis announces positive FDA Pre-IND feedback supporting Privosegtor development strategy for treatment of acute multiple sclerosis relapses.

-------- Link if available ----------

No Link available